Novartis Buys GlaxoSmithKline's Oncology Unit for $14.5 Billion

Discussion in 'GlaxoSmithKline' started by Anonymous, Apr 22, 2014 at 2:42 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Wow. Didn't see that coming.
     

  2. Anonymous

    Anonymous Guest

    Me either and Novartis has a history of slashing the sales force.
     
  3. Anonymous

    Anonymous Guest

    And GSK doesn't?
     
  4. Anonymous

    Anonymous Guest

    Smart move.
     
  5. Anonymous

    Anonymous Guest

    Really?? You didn't. Dimwitty has been unhappy with oncology for years now as shown by the continual shrinking of resources and budget. It's true that GSK isn't a player and won't be in oncology. Management set the wheels in motion for this a long time ago. Sales in oncology stunk as all of you know too well because you've been too busy buying pizza for docs that don't prescribe GSK products.
     
  6. Anonymous

    Anonymous Guest

    But Oncology is the bright spot in GSKs future! Oh, yeah, we failed to mention the bright spot is where we sell it off.
     
  7. Anonymous

    Anonymous Guest

    Let's see - we actually managed to get some successful new products on the market - then we sell them off and call it quits.

    Is the plan to stick with areas that we suck at?

    What's wrong with being #14 in oncology if you can still make a profit. It's better than being #0 in oncology.
     
  8. Anonymous

    Anonymous Guest

    Incredible that we sell oncology for $14 billion which seems great however as the poster above said we go from number #14 to actually not even on the list and then we turn around and take $7 billion of what we just made and pay for a vaccine business unit that reportedly lost $200-250 million last year! Incredible Wall Street not sniffing this out because it doesn't pass the smell test.
     
  9. Anonymous

    Anonymous Guest

    This is what happens when sales people have to concentrate on taking tests and simulations and not on selling any products. I doubt very much that our senior leadership will be here once norvartis takes over. tick tock tick tock.
     
  10. Anonymous

    Anonymous Guest

    I wish I could go back to selling asthma stuff......that was fun!
     
  11. Anonymous

    Anonymous Guest

    Not anymore!
     
  12. Anonymous

    Anonymous Guest

    You speak like you are personally going to see some of the money. Just go study and get your paycheck while it lasts.
     
  13. Anonymous

    Anonymous Guest

    Heres the company line:

    1. That oncology business that we've been trumpeting for the last few years, really sucks because it lacks an immunotherapy asset in the pipeline.
    2. $14.5Bn, or $16Bn if you count the milestone, is an incredible price for this business since we'll never be a player in this field.
    3. All that stuff we told you during the earnings release about being well positioned in one of the key therapeutic areas for the next 30 years, forget that, we needed to say something.
    4. Now we're focused on respiratory, vaccines, and consumer. (We're gonna slash the hell out of that NVS vaccines' cost structure in order to make the business profitable.) Ignore the overlap in the portfolios, it isn't relevant.
    5. Look at all these new OTC assets that we got. Never mind that they look suspiciously like the ones we just sold a few years ago. We couldn't grow those, but we sure can grow these because, well --- they're already growing.
    6. Oh yeah, AND DON'T FORGET THE SHARE BUYBACK BECAUSE THAT'S OUR REAL CORE COMPETENCY!

    And here's the best part. If people who reported to you or me bribed every damned doctor on Earth, anybody think we'd be getting a raise?
     
  14. Anonymous

    Anonymous Guest



    On the lack of immunotherapeutics, does that mean the MAGRIT and DERMA trials for MAGE are negative ?

    Also, what happens to the vaccines/oncology crossover projects and their personel ?

    Also, considering Novartis own such a large stake in Roche/Genentech anyway, what would they want GSK's portfolio or products for ?
     
  15. Anonymous

    Anonymous Guest

    keep speculating and wondering what if, you little bitches. Bye bye because Novartis will gut you like pigs. see ya you no talent losers. go crawling back to primary care. this is funny to see you idiots crying in your beer!!
     
  16. Anonymous

    Anonymous Guest

    $14.5 billion and we had roommates in Chicago to save money
     
  17. Anonymous

    Anonymous Guest

    DOA
     
  18. Anonymous

    Anonymous Guest

    MAGRIT was cancelled a few weeks ago. DERMA is running a while longer looking at patients with a certain gene expression only - very small group.
     
  19. Anonymous

    Anonymous Guest

    "that reportedly lost $200 million"....wrong- vaccines was and will be a very profitable BU for GSK
     
  20. Anonymous

    Anonymous Guest

    It's the Novartis vaccine unit which is the money loser. Comments below from VacZine Analytics on the Novartis business.

    Novartis Vaccines and Diagnostics reported $1987m sales for 2013 an increase on the $1858m recorded in 2012 (3). Again Novartis cited strong growth for Menveo its conjugate vaccine for invasive meningococcal disease (ACWY) but also pre-pandemic (H7N9) and seasonal influenza sales despite not yet switching to a Quadrivalent format which is actively in development. A small amount of private sales for meningococcal serogroup b vaccine were also recorded partly due to University outbreaks in the US e.g. Princeton. The company still waits any further evaluation from the UK JCVI regarding the possible implementation of the UK immunisation programme despite the same committee previously stating the vaccine wouldn't be cost-effective at any price.
    Because the vaccines and diagnostics division remains loss-making unit for its corporate parent a number of times, senior Novartis personnel have mentioned, they are in discussions to divest the unit, which was acquired back in 2007. The company is known to be in discussions with Merck & Co as part of a possible trade for its OTC drugs business (4). Other bidders, most likely the other vaccine major players will be considering the unit behind-the-scenes.